Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Study of the Safety and Effectiveness of HAC 22L for Improving Midface Volume

NCT05818709 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05818709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05818709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Study of the Safety and Effectiveness of HAC 22L for Improving Midface Volume
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2023
Completion date
December 5, 2025
Enrollment
61 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

facial volume deficit